Skip to main content
Top
Published in: Lung 4/2016

01-08-2016

Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism

Authors: Anish Desai, MD, Amishi Desai, Rose Calixte, Malaygiri Aparnath, Alexander Hindenburg, Steve Salzman, Joseph P. Mathew

Published in: Lung | Issue 4/2016

Login to get access

Abstract

Background

Recent studies have demonstrated non-inferiority of rivaroxaban when compared to warfarin for the treatment of pulmonary embolism and deep venous thrombosis. Analysis of data from the EINSTEIN trials has demonstrated that patients who received rivaroxaban had a shorter length of stay (LOS) compared to those who received warfarin. However, these trials had strict inclusion and exclusion criteria, and were designed for a different primary outcome. Also, data from these closely monitored clinical trials may not reflect the daily practice of medicine.

Objectives

To clarify this issue further, we performed a retrospective analysis at our institution, comparing the LOS between patients discharged on rivaroxaban and other conventional anticoagulants (warfarin, enoxaparin, and enoxaparin with warfarin).

Methods

This was a retrospective study of consecutive patients admitted to our institution from January 2011 to July 2014 with newly diagnosed venous thromboembolism (VTE). Inclusion criteria were age > 18 years and objective confirmation of VTE. Exclusion criteria included diagnosis of VTE 24 h after admission, contraindication to anticoagulation, treatment with fibrinolytic agents, patients already on anticoagulation, and pregnancy. Out of 1553 consecutive patients diagnosed with VTE, a total of 414 patients met the eligibility criteria. These patients were further subdivided into four groups based on their discharge anticoagulant: rivaroxaban, warfarin, enoxaparin, and warfarin with enoxaparin.

Results

Patients discharged on rivaroxaban had a significantly shorter LOS compared with patients discharged on warfarin (3.5 vs. 7.0 days; p < 0.001), but not when compared to those discharged on enoxaparin alone (3.0 days) or enoxaparin with warfarin (4.0 days) (p > 0.05). The hospital incidence of bleeding and the 6-month readmission rates were not different among the different anticoagulants.

Conclusions

In patients admitted with newly diagnosed VTE, those discharged on rivaroxaban had a significantly shorter LOS compared to those discharged on warfarin. In the appropriate subset of patients with VTE, treatment with rivaroxaban may result in significant cost savings for the hospital.
Literature
1.
go back to reference Oger E (2000) Incidence of venous thromboembolism: a community-based study in western France. Thromb Haemost 83:657–660PubMed Oger E (2000) Incidence of venous thromboembolism: a community-based study in western France. Thromb Haemost 83:657–660PubMed
2.
go back to reference Spencer FA, Emery C, Lessard D et al (2006) The Worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 21:722–727CrossRefPubMedPubMedCentral Spencer FA, Emery C, Lessard D et al (2006) The Worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 21:722–727CrossRefPubMedPubMedCentral
3.
go back to reference Heit JA, Cohen AT, Anderson FA Jr (2005) Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 106:910 Heit JA, Cohen AT, Anderson FA Jr (2005) Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 106:910
4.
go back to reference Goldhaber SZ, Visani L, De Rosa M (1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353(9162):1386–1389CrossRefPubMed Goldhaber SZ, Visani L, De Rosa M (1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353(9162):1386–1389CrossRefPubMed
5.
go back to reference Prandoni P, Lensing AW, Büller HR et al (1992) Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339(8791):441–445CrossRefPubMed Prandoni P, Lensing AW, Büller HR et al (1992) Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339(8791):441–445CrossRefPubMed
6.
go back to reference The Columbus Investigators (1997) Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337(10):657–662CrossRef The Columbus Investigators (1997) Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337(10):657–662CrossRef
7.
go back to reference Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352CrossRefPubMed Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352CrossRefPubMed
8.
go back to reference EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297CrossRef EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297CrossRef
9.
go back to reference EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510CrossRef EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510CrossRef
10.
go back to reference AMPLIFY Investigators, Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808CrossRef AMPLIFY Investigators, Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808CrossRef
11.
go back to reference Bookhart BK, Haskell L, Bamber L et al (2014) Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the north American EINSTEIN clinical trial program. J Med Econ 17(10):691–695CrossRefPubMed Bookhart BK, Haskell L, Bamber L et al (2014) Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the north American EINSTEIN clinical trial program. J Med Econ 17(10):691–695CrossRefPubMed
12.
go back to reference Van Bellen B, Bamber L, Correa de Carvalho F et al (2014 May) Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 30(5):829–837CrossRefPubMed Van Bellen B, Bamber L, Correa de Carvalho F et al (2014 May) Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 30(5):829–837CrossRefPubMed
13.
go back to reference Hospital adjusted expenses per inpatient day (2013) The Henry J. Kaiser Family Foundation Hospital adjusted expenses per inpatient day (2013) The Henry J. Kaiser Family Foundation
14.
go back to reference Schulman S, Anderson DR, Bungard TJ et al (2010) Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost 8:2192–2200CrossRefPubMed Schulman S, Anderson DR, Bungard TJ et al (2010) Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost 8:2192–2200CrossRefPubMed
15.
go back to reference Catherine JM, Ciarametaro M, Hahn B et al (2011) Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 42:112–118CrossRef Catherine JM, Ciarametaro M, Hahn B et al (2011) Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 42:112–118CrossRef
16.
go back to reference Bamber L, Wang MY, Prins MH et al (2013) Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 110(4):732–741CrossRefPubMed Bamber L, Wang MY, Prins MH et al (2013) Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 110(4):732–741CrossRefPubMed
17.
go back to reference Lin J, Lingohr-Smith M, Kwong WJ (2014 Feb) Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a US payer perspective. J Manag Care Pharm 20(2):174–186PubMed Lin J, Lingohr-Smith M, Kwong WJ (2014 Feb) Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a US payer perspective. J Manag Care Pharm 20(2):174–186PubMed
18.
go back to reference Guyatt GH, Akl EA, Crowther M et al (2012) Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2_Suppl):7S–47SCrossRefPubMedPubMedCentral Guyatt GH, Akl EA, Crowther M et al (2012) Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2_Suppl):7S–47SCrossRefPubMedPubMedCentral
19.
go back to reference Specifications manual for national hospital inpatient quality measures discharges 01-01-15 (1Q15) through 09-30-15 (3Q15). Version 4.4 Specifications manual for national hospital inpatient quality measures discharges 01-01-15 (1Q15) through 09-30-15 (3Q15). Version 4.4
20.
go back to reference Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011 Oct 4) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573–1579CrossRefPubMed Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011 Oct 4) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573–1579CrossRefPubMed
21.
go back to reference Marlu R, Hodaj E, Paris A et al (2012 Aug) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217–224CrossRefPubMed Marlu R, Hodaj E, Paris A et al (2012 Aug) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217–224CrossRefPubMed
Metadata
Title
Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism
Authors
Anish Desai, MD
Amishi Desai
Rose Calixte
Malaygiri Aparnath
Alexander Hindenburg
Steve Salzman
Joseph P. Mathew
Publication date
01-08-2016
Publisher
Springer US
Published in
Lung / Issue 4/2016
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-016-9898-8

Other articles of this Issue 4/2016

Lung 4/2016 Go to the issue